Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.51 |
| ▸ | CA2 | P00918 | 6/20 | 0.51 |
| ▸ | CA4 | P22748 | 6/20 | 0.51 |
| ▸ | CA6 | P23280 | 6/20 | 0.51 |
| ▸ | PARP1 | P09874 | 10/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GUSB | P08236 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.40 |
| ▸ | MAP3K10 | Q02779 | 1/20 | 0.40 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2763222 | 0.81 | PARP1 (0.70) | CA1CA2CA4CA6PARP1 | |
| SCHEMBL4833607 | 0.80 | CA1 (0.48) | CA1CA2CA4CA6PARP1 | |
| SCHEMBL5465260 | 0.78 | CHEK1 (0.40) | CA1CA2CA4CA6PARP1 | |
| SCHEMBL2763163 | 0.77 | PARP1 (0.46) | CA1CA2CA4CA6PARP1 | |
| SCHEMBL7200645 | 0.77 | CA1 (0.45) | CA1CA2CA4CA6PARP1 | |
| SCHEMBL4863324 | 0.76 | KMT2A (0.45) | CA1CA2CA4CA6PARP1 | |
| SCHEMBL6899170 | 0.75 | PARP1 (0.45) | CA1CA2CA4CA6PARP1 | |
| SCHEMBL15910972 | 0.72 | CA1 (0.44) | CA1CA2CA4CA6HPGD | |
| SCHEMBL2784194 | 0.71 | CA1 (0.39) | CA1CA2CA4CA6PARP1 | |
| SCHEMBL8796473 | 0.70 | MAPT (0.47) | CA1CA2CA4CA6PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262016-A1 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1420785-A2 | SUBSTITUTED INDENO 1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20030096833-A1 | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2003-05-22 | — | — | US | disclosed |
| WO-2003020700-A2 | SUBSTITUTED INDENO[1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262016-A1 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | CYP3A7, CYP3A5, ABCG2 | CA1 4670/4885CA2 3914/4885CA4 3112/4885 |
| US-20030096833-A1 | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof | UGT1A1, XPO1, IPO7 | CA1 4597/4885CA2 3994/4885CA4 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.